A groundbreaking new drug named AOH1996 has demonstrated remarkable potential in early-stage studies by effectively eliminating solid cancerous tumors.
The drug, a chemotherapy agent, distinguishes itself by sparing healthy cells, thereby minimizing adverse side effects.
In the past, PCNA was considered a challenging target for therapy due to its crucial role in encouraging tumor growth through DNA replication and repair of cancerous cells.
Despite these promising results, AOH1996 is still in the early stages of development.
She described the drug’s action as similar to a snowstorm that shuts down only the flights carrying cancer cells in and out of the terminal.